- First Quarter Sales Up 7% to $113.2 Million -
- EPS Increases 35% to $0.35
UTICA, N.Y., April 23 /PRNewswire-FirstCall/ --
CONMED Corporation (Nasdaq: CNMD) today announced financial results for the
quarter ended March 31, 2002.
Sales for the first quarter increased 7% to $113.2 million from
$105.9 million in the comparable quarter last year. Net income was
$9.1 million, 51% above the $6.0 million reported in last years first quarter.
Earnings per diluted share grew 35% to $0.35 from $0.26 in the same quarter in
2001. On January 1, 2002, the Company adopted the provisions of FAS 142
relative to the cessation of goodwill amortization. This change caused net
income to increase $1.4 million and earnings per share to increase $.05.
Arthroscopy sales increased 3% to $41.3 million from $40.2 million in the
same period last year. Powered instrument sales declined 7% to $28.4 million
compared to $30.6 million in the first quarter of 2001. Sales of powered
surgical instruments have been stable since the second quarter of 2001 at
approximately $28 million per quarter. As previously announced, the Company
introduced its PowerPro(TM) Battery Powered Instrument line of powered
surgical instruments in February 2002, replacing its older versions of battery
powered instruments. First shipments of the product line were made in March
2002. Accordingly, sales of Powered Surgical Instruments for the quarter were
in line with expectations.
Electrosurgery revenues were $16.8 million, a 12% increase from the
$15.0 million recorded in first quarter 2001. Endoscopy revenues grew
significantly to $9.4 million from $2.5 million in the same period last year,
reflecting a better than anticipated performance from the Imagyn product line
acquired in July 2001. Sales of Patient Care Products were $17.3 million
compared to $17.6 million in the first quarter 2001.
In the three months ended March 31, 2002, the Company reduced its balance
sheet debt by $10 million from operating cash flows. EBITDA amounted to
$25.8 million for the quarter.
Joseph J. Corasanti, President and Chief Operating Officer, commented, "I
am very pleased with the strong performance of the electrosurgery products and
the endoscopy products in the first quarter of 2002. Arthroscopy sales for
the quarter were at record levels, exceeding first quarter 2001 amounts and
showing sequential growth over an especially strong fourth quarter of 2001.
In addition, I am encouraged by the feedback we have received from the medical
community regarding our new PowerPro(TM) Battery Powered Instrument Line and
expect it to fuel revenue growth in our Powered Surgical Instruments business
going forward."
Mr. Corasanti continued, "Looking ahead, we continue to believe that new
product launches and market growth in our existing product lines will produce
total revenue growth of 8% in 2002 over 2001, including the full year effects
of the Imagyn acquisition. We expect operating efficiencies to generate
earnings per share growth of 35% to 40% over 2001, including the elimination
of goodwill amortization which will add $0.22 per share to our 2002 earnings.
For the second quarter, we anticipate revenues to be in the range of $108 to
$112 million with diluted earnings per share of $0.32 to $0.35."
CONMED is a medical technology company specializing in instruments,
implants, and video equipment for arthroscopic sports medicine, and powered
surgical instruments (drills and saws) for orthopedic, ENT, neuro-surgery, and
other surgical specialties. The Company is also a leading developer,
manufacturer and supplier of RF electrosurgery systems used routinely to cut
and cauterize tissue in over ninety percent of all surgical procedures
worldwide, endoscopy products such as trocars, clip appliers, scissors, and
surgical staplers, and a full line of ECG electrodes for heart monitoring and
other patient care products. Headquartered in Utica, Now York, the Company's
2,500 employees distribute its products worldwide from eight manufacturing
locations.
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which could
cause actual results, performance or trends, including the above mentioned
anticipated revenues and earnings, to differ materially from those expressed
in the forward-looking statements herein or in previous disclosures. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct. In addition to general
industry and economic conditions, factors that could cause actual results to
differ materially from those discussed in the forward-looking statements in
this press release include, but are not limited to: (i) the failure of any one
or more of the assumptions stated above, to prove to be correct; (ii) the
risks relating to forward-looking statements discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2001; (iii)
cyclical purchasing patterns from customers, end-users and dealers; (iv)
timely release of new products, and acceptance of such new products by the
market; (v) the introduction of new products by competitors and other
competitive responses; (vi) the possibility that any new acquisition or other
transaction may require the Company to reconsider its financial assumptions
and goals/targets; and or (vii) the Company's ability to devise and execute
strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended March 2001 and 2002
(In thousands except per share amounts)
(unaudited)
2001 2002
Net sales $105,909 $113,205
Cost of sales 49,674 54,104
Selling and administrative expense 34,829 34,468
Research and development expense 3,696 3,824
88,199 92,396
Income from operations 17,710 20,809
Interest expense, net 8,331 6,628
Income before income taxes 9,379 14,181
Provision for income taxes 3,376 5,105
Net income $6,003 $9,076
Per share data
Net income
Basic $.26 $.36
Diluted .26 .35
Weighted average common shares
Basic 23,057 25,397
Diluted 23,307 25,969
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
ASSETS
(unaudited)
December March
2001 2002
Current assets:
Cash and cash equivalents $1,402 $2,634
Accounts receivable, net 51,188 50,893
Inventories 107,390 109,951
Other current assets 4,569 4,803
Total current assets 164,549 168,281
Property, plant and equipment, net 91,026 92,028
Goodwill and other assets, net 446,033 446,641
Total assets $701,608 $706,950
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $73,429 $73,914
Accrued interest 4,954 1,573
Other current liabilities 41,454 45,360
Total current liabilities 119,837 120,847
Long-term debt 262,500 252,077
Other long-term liabilities 35,637 38,815
Total liabilities 417,974 411,739
Shareholders' equity:
Capital accounts 160,591 162,576
Retained earnings 128,240 137,316
Accumulated other comprehensive loss (5,197) (4,681)
Total equity 283,634 295,211
Total liabilities and shareholders' equity $701,608 $706,950
OTHER FINANCIAL INFORMATION
(unaudited, in thousands)
Three months ended
March
2001 2002
EBITDA $24,922 $25,795
Depreciation 2,185 2,206
Amortization 5,027 2,780
Capital expenditures 3,867 3,208
SOURCE CONMED Corporation
 back to top
Related links:
http://www.conmed.com
Company News On-Call:
http://www.prnewswire.com/comp/201850.html
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; Investors - Theresa Vogt or
Lanie Fladell, or Media - Dan Budwick, all of Morgen-Walke
Associates, +1-212-850-5600, for CONMED Corporation
|
